Why Progyny, Inc.’s (PGNY) Stock Is Up 5.27%
As of Wednesday, October 07, Progyny, Inc.’s PGNY share price has surged by 5.27%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Progyny, Inc., a benefits management company, provides fertility, family building, and women’s health benefits solutions in the United States. It offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides access to the medications needed during their treatment and offers care management services, as well as pregnancy and postpartum, menopause and midlife, benefit and leave navigation, and parent and child wellbeing solutions. In addition, it provides assistance service program where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
Commentary & Analysis
Why Progyny, Inc.’s (PGNY) Stock Is Down 9.33%
As of Friday, August 07, Progyny, Inc.’s PGNY share price has dipped by 9.33%, which has investors questioning if this is right time to buy.Michael Rose
Is Progyny, Inc. (PGNY) Overvalued?
We dive into why Progyny, Inc. (PGNY) could be considered overvalued on 2026-08-04, based on AAII’s Value Score and Grade.Jenna Brashear
Which Is a Better Investment, NeoGenomics, Inc. or Progyny, Inc. Stock?
Learn more about whether NeoGenomics, Inc. or Progyny, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Rosalio Madrigal
Which Is a Better Investment, agilon health, inc. or Progyny, Inc. Stock?
Learn more about whether agilon health, inc. or Progyny, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Tudor Pop
Financial Summary
| Share Statistics | PGNY | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $2,158.3 | $1,826.9 | 56% |
|
| Shares Out (Mil) | 82.1 | 80.1 | 58% |
|
| Institutional Ownership | 98.3% | 86.1% | 78% |
|
| Float (Mil) | 70.2 | 56.2 | 54% |
|
| Beta | 0.99 | 0.81 | 59% |
|
| Avg Daily Volume (000s) | 850 | 594 | 67% |
|
| Price Change (52-week) |
44.3% | 78.7% | 84% |
|
| Growth | PGNY | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 30.2% | 10.4% | 90% |
|
| Net Income (5yr) | 4.7% | (0.5%) | 47% |
|
| EPS (5yr) | 6.7% | 2.1% | 41 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (36.1%) | (17.4%) | 14% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 9 | 9 | 9 | |
| Current EPS | $0.509 | $2.082 | $2.313 | |
| Month Ago EPS | $0.509 | $2.085 | $2.320 | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | $0.523 | $2.057 | $2.248 | |
| Year/Year Chg | 49.7% | 220.3% | 290.0% | |
| Financials | PGNY | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $1,311 | $1,504 | 54% |
|
| Net Income (TTM) (Mil) | $79 | $28 | 59% |
|
| EPS (TTM) | $0.952 | $0.200 | 60% |
|
| Operating Cash Flow (TTM) (Mil) | $201 | $162 | 59% |
|
| Net Cash Flow (TTM) (Mil) | $17 | $2 | 60% |
|
| Long-Term Debt (Q1) (Mil) | $23 | $375 | 34% |
|
| Enterprise Value (Q1) (Mil) | $1,803 | $2,330 | 48% |
|
| Valuation | PGNY | Industry Median |
Percentile (All Stocks) |
|
| P/B | 4.77 | 2.98 | 79% |
|
| P/E | 31.0 | 26.4 | 72% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 4.6 | 1.1 | 86% |
|
| Ratios | PGNY | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 24.6% | 27.4% | 27% |
|
| Net Margin | 6.0% | 1.3% | 51% |
|
| ROA | 10.6% | 2.2% | 88% |
|
| ROE | 16.2% | 7.1% | 73% |
|
| Liabilities to Assets | 36.7% | 61.5% | 28% |
|
| F-Score | 8 | 5 | 93% |
|
Progyny, Inc. did not pass any screens on 10/26/2026.
